ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Esperion Therapeutics, Inc. ?
1
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Operating profit has grown by an annual rate 10.58% of over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -2.53
2
The company declared very negative results in Mar'25 after positive results in Dec'24
- RAW MATERIAL COST(Y) Grown by 21.02% (YoY)
- CASH AND EQV(HY) Lowest at USD 178.51 MM
- INTEREST(Q) Highest at USD 22.05 MM
3
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 61.39%, its profits have fallen by -409.5%
4
Reducing Promoter Confidence
- Promoters have decreased their stake in the company by -4.47% over the previous quarter and currently hold 2.52% of the company
- Promoters decreasing their stake may signify reduced confidence in the future of the business
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Esperion Therapeutics, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Esperion Therapeutics, Inc.
65.82%
-0.15
83.70%
S&P 500
14.9%
0.77
19.29%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
6.78%
EBIT Growth (5y)
10.58%
EBIT to Interest (avg)
-2.53
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.12
Sales to Capital Employed (avg)
1.36
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
80.20%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-1.54
EV to EBIT
-40.98
EV to EBITDA
-41.09
EV to Capital Employed
21.34
EV to Sales
3.96
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-52.08%
ROE (Latest)
Negative BV
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
Bullish
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend10What is working for the Company
NET PROFIT(HY)
Higher at USD -44.06 MM
DEBT-EQUITY RATIO
(HY)
Lowest at -112.67 %
INVENTORY TURNOVER RATIO(HY)
Highest at 1.35 times
NET SALES(Q)
Highest at USD 87.31 MM
-13What is not working for the Company
RAW MATERIAL COST(Y)
Grown by 21.02% (YoY
CASH AND EQV(HY)
Lowest at USD 178.51 MM
INTEREST(Q)
Highest at USD 22.05 MM
PRE-TAX PROFIT(Q)
At USD -31.33 MM has Fallen at -22.47%
NET PROFIT(Q)
At USD -31.33 MM has Fallen at -22.47%
Here's what is working for Esperion Therapeutics, Inc.
Debt-Equity Ratio
Lowest at -112.67 % and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Net Sales
Highest at USD 87.31 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Net Sales
At USD 87.31 MM has Grown at 30.25%
over average net sales of the previous four periods of USD 67.03 MMMOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Inventory Turnover Ratio
Highest at 1.35 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its inventory faster
Inventory Turnover Ratio
Here's what is not working for Esperion Therapeutics, Inc.
Interest
Highest at USD 22.05 MM
in the last five periods and Increased by 7.64% (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (USD MM)
Pre-Tax Profit
At USD -31.33 MM has Fallen at -22.47%
over average net sales of the previous four periods of USD -25.58 MMMOJO Watch
Near term Pre-Tax Profit trend is negative
Pre-Tax Profit (USD MM)
Net Profit
At USD -31.33 MM has Fallen at -22.47%
over average net sales of the previous four periods of USD -25.58 MMMOJO Watch
Near term Net Profit trend is negative
Net Profit (USD MM)
Cash and Eqv
Lowest at USD 178.51 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
Raw Material Cost
Grown by 21.02% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
